At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,826 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Agrylin Capsules 0.5 mg Drug Use-Result Survey
In Brief
An observational study for Essential Thrombocythemia (ET). Completed, enrolled 1,826 participants across 488 sites.
Detailed Summary
The objective of this survey is to collect data to evaluate the safety and efficacy of anagrelide hydrochloride in the post-marketing phase in participants diagnosed with Essential Thrombocythemia (ET).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Thrombocythemia (ET)
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartNov 2014
First PostedAug 2018
Primary CompletionMar 2021
TodayJul 2026
First PostedAug 10, 2018
Enrollment StartNov 25, 2014
Primary CompletionMar 11, 2021
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 7.9 years ago